A multi-center, phase 1-2A, open-label, dosage-escalation and randomized, double-blinded, placebo-controlled study of dimebon [dimebolin] in subjects with Huntington's disease.

Trial Profile

A multi-center, phase 1-2A, open-label, dosage-escalation and randomized, double-blinded, placebo-controlled study of dimebon [dimebolin] in subjects with Huntington's disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2009

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Acronyms DIMOND
  • Sponsors Medivation
  • Most Recent Events

    • 14 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Feb 2008 Status changed from completed to in progress as Medivation have reported that the phase II part is ongoing.
    • 19 Feb 2008 Medivation have reported that the phase I tolerability part of this trial has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top